AC5

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)

Retrieved on: 
Monday, May 6, 2024
Chin Na, OTCQB, Food, Symposium, AC5, Patient, SAWC, Human, Wound healing, Therapy, Orlando World Center Marriott, User experience, Nursing

FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.

Key Points: 
  • FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.
  • Arch’s team will be available for discussions with clinicians throughout the Symposium and at Arch’s booth (#535) in the exhibit hall.
  • Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, “We are delighted that AC5 Advanced Wound System will be presented again at this important Symposium.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.

Arch Therapeutics Provides Year End Operational Update

Retrieved on: 
Thursday, November 9, 2023
SAWC, HCPCS, Food, Innovation, Medicare, Arch, OTCQB, Foot, AC5, Symposium, Therapy, Centers for Medicare & Medicaid Services, CMS, Wound healing, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Mobile phone, Health insurance, A2020

FRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”).

Key Points: 
  • FRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”).
  • A more detailed summary of key milestones and achievements from the fiscal year ended September 30, 2023 is provided below.
  • At SAWC Spring 2023, Arch introduced the theme “Experience the Difference” to highlight AC5’s technology, application, wound coverage, and efficacy.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.

Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)

Retrieved on: 
Thursday, November 2, 2023
Food, Lower, Arch, OTCQB, AC5, Pressure, Caesars Palace, Therapy, Patient, Human, Failure, Wound healing, Food and Drug Administration Amendments Act of 2007, Nursing, Pharmaceutical industry, MD

FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2023 Symposium on Advanced Wound Care Fall Meeting (“SAWC Fall”), which takes place at Caesars Palace, Las Vegas, from November 2-5, 2023.

Key Points: 
  • FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2023 Symposium on Advanced Wound Care Fall Meeting (“SAWC Fall”), which takes place at Caesars Palace, Las Vegas, from November 2-5, 2023.
  • On Sunday, November 5, 2023 from 9:10 A.M. EST – 11:20 A.M. EST, AC5 will be featured in the Advanced Wound Care Therapy for the Lower Extremity: Hands-On Skills Lab.
  • Terrence W. Norchi, MD, President and CEO of Arch Therapeutics said, “SAWC presents an important opportunity to showcase our proprietary self-assembling peptide technology to wound care providers.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.

Arch Therapeutics Provides AC5® Commercialization Update

Retrieved on: 
Wednesday, September 13, 2023
CMS, Amputation, Centers for Medicare & Medicaid Services, Calendar, OTCQB, Medicare, AC5, Criticism of the Food and Drug Administration, Pressure, Patient, Risk, Growth, Therapy, Death, Food, Wound healing, Pharmaceutical industry, Health insurance, A2020, MD

FRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5® Advanced Wound System.

Key Points: 
  • FRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5® Advanced Wound System.
  • “The establishment of coverage and payment decisions from commercial payors and CMS contractors is an important element of our growth strategy for AC5.
  • We expect to build on our recent sales momentum throughout 2023 and 2024,” stated Terrence Norchi, MD, President and CEO of Arch.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.

Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)

Retrieved on: 
Tuesday, April 25, 2023
Surgeon, National Harbor, Maryland, Centers for Medicare & Medicaid Services, SAWC, OTCQB, Arch, Medicare, AC5, A2020, Symposium, Therapy, Hospital, Pharmaceutical industry, MD

FRAMINGHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company will be exhibiting its AC5® Advanced Wound System (“AC5”) at the Symposium on Advanced Wound Care (“SAWC”) Spring 2023, which takes place at National Harbor, MD from April 26-30, 2023.

Key Points: 
  • FRAMINGHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company will be exhibiting its AC5® Advanced Wound System (“AC5”) at the Symposium on Advanced Wound Care (“SAWC”) Spring 2023, which takes place at National Harbor, MD from April 26-30, 2023.
  • SAWC Spring 2023 represents the first clinical conference opportunity for Arch to present AC5 since the Centers for Medicare and Medicaid Services (“CMS”) established a new AC5-dedicated Level II Healthcare Common Procedure Coding System (“HCPCS”) code, “A2020”, effective April 1, 2023.
  • Arch will introduce clinicians to its product theme, “Experience the Difference,” which highlights AC5’s technology, application, wound coverage, and efficacy in wounds for which AC5 is indicated.
  • A pre-conference announcement was sent to surgeons and other clinicians inviting them to visit Arch at SAWC to learn more about both the product and A2020.

Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect

Retrieved on: 
Wednesday, April 5, 2023
Chin Na, CMS, Centers for Medicare & Medicaid Services, OTCQB, Center for Medicare and Medicaid Innovation, AC5, A2020, Medicare, Food and Drug Administration Amendments Act of 2007, Amputation, Patient, HCPCS, Therapy, Food, Wound healing, Pharmaceutical industry, Hospital

FRAMINGHAM, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Centers for Medicare and Medicaid Services (“CMS”) Level II Healthcare Common Procedure Coding System (“HCPCS”) code dedicated to the Company’s AC5® Advanced Wound System (“AC5”) went into effect on April 1, 2023.

Key Points: 
  • FRAMINGHAM, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Centers for Medicare and Medicaid Services (“CMS”) Level II Healthcare Common Procedure Coding System (“HCPCS”) code dedicated to the Company’s AC5® Advanced Wound System (“AC5”) went into effect on April 1, 2023.
  • Dan Yrigoyen, Vice President of Sales of Arch Therapeutics, said, “Since the announcement last month that CMS created a HCPCS code for AC5 Advanced Wound System, we have had new product inquiries by potential customers in offices and other outpatient facilities who previously indicated they were unwilling to order AC5 absent an available dedicated reimbursement code.
  • While a code does not guarantee coverage or payment, its effectiveness marks a key commercialization milestone for the Company,” concluded Mr. Yrigoyen.
  • AC5 is a proprietary synthetic self-assembling wound care product designed to provide clinicians with multi-modal support and utility across all phases of wound healing.

Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services

Retrieved on: 
Thursday, March 9, 2023
Pressure, CMS, Chin Na, Centers for Medicare & Medicaid Services, Arch, Food and Drug Administration Amendments Act of 2007, OTCQB, Medicare, Therapy, Patient, Food, AC5, HCPCS, MD, Wound healing, Pharmaceutical industry

FRAMINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Centers for Medicare and Medicaid Services (“CMS”) established a new Level II Healthcare Common Procedure Coding System (“HCPCS”) code dedicated to the Company’s AC5® Advanced Wound System (“AC5”).

Key Points: 
  • FRAMINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Centers for Medicare and Medicaid Services (“CMS”) established a new Level II Healthcare Common Procedure Coding System (“HCPCS”) code dedicated to the Company’s AC5® Advanced Wound System (“AC5”).
  • The new HCPCS code, “A2020,” will become effective on April 1, 2023, creating a new pathway for reimbursement of AC5.
  • Terrence Norchi, MD, Chief Executive Officer of Arch Therapeutics, said, “We have been eagerly anticipating the announcement of a unique HCPCS code for AC5.
  • Many clinicians have expressed interest in AC5 but have been hesitant to order in the absence of a dedicated HCPCS code.

Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities

Retrieved on: 
Tuesday, March 7, 2023
Medicine, Arch, OTCQB, Therapy, Trauma center, Surgeon, Department of Defense Serum Repository, Trauma, Department of Defence, Mouth ulcer, AC5, Trauma Center, Indian Health Service, Patient, United States Department of Veterans Affairs, Nursing, Pharmaceutical industry

These additional representatives will be deployed to optimize opportunities in newly created sales regions and in current regions that have had initial and restocking orders for AC5.

Key Points: 
  • These additional representatives will be deployed to optimize opportunities in newly created sales regions and in current regions that have had initial and restocking orders for AC5.
  • “Expansion of our sales footprint is a key step in our commercialization plan, particularly for the government channel,” stated Dan Yrigoyen, Vice President of Sales of Arch Therapeutics.
  • “While the sales cycle is long, we have experienced an increase in new and recurring sales orders in areas where Arch management directly provides dedicated selling and clinical support to our independent sales representatives.
  • We believe at this stage of product rollout, that we can further advance our commercialization efforts by deploying additional qualified sales representatives who have a proven track record selling advanced wound care products in VA and other government facilities.

Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System

Retrieved on: 
Wednesday, January 18, 2023
CWS, ABPM, Icahn School of Medicine at Mount Sinai, Wound healing, Foot, Therapy, Hyperbaric medicine, American Board of Commissioners for Foreign Missions, WAFL, DPM, Diving Medical Advisory Council, AC5, CWSP, FACPM, General surgery, FACS, Practice management, OTCQB, FASPS, Pharmaceutical industry, Medicine, Dentistry, MD, Podiatry

FRAMINGHAM, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced the formation of a medical advisory board (the “Medical Advisory Board”) comprised of respected wound care professionals across multiple medical specialties, including vascular surgery, podiatric medicine, and foot and ankle surgery.

Key Points: 
  • FRAMINGHAM, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced the formation of a medical advisory board (the “Medical Advisory Board”) comprised of respected wound care professionals across multiple medical specialties, including vascular surgery, podiatric medicine, and foot and ankle surgery.
  • The Company believes that the Medical Advisory Board will support the strategic alignment of patient, payor, and provider goals to help advance the ongoing commercialization of its AC5® Advanced Wound System (“AC5”).
  • “We are honored to draw on the expertise of these industry leaders as we continue to pursue our mission of creating a better patient experience for those with challenging chronic and acute surgical wounds, while simultaneously improving value for both payors and medical practices,” stated Terrence W. Norchi, MD, President and Chief Executive Officer of Arch.
  • “We believe the combined experience and expertise of this Medical Advisory Board will help drive the continued adoption and utilization of AC5, as well as potentially shape our work for years to come.”
    Arch welcomes the following six members to its Medical Advisory Board:
    Dr. Gregory A. Bohn, MD, FACS, ABPM/UHM, MAPWCA, CWSP, board-certified in General Surgery and Hyperbaric Medicine, and President of the American Board of Wound Healing;
    Dr. Matthew G. Garoufalis, DPM, FASPS, FACPM, CWS, board-certified in Podiatric Medicine and Foot and Ankle Surgery, Chief Medical Officer of Advanced Oxygen Therapy Inc., and key opinion leader on diabetic foot care, lower extremity wound care, and limb salvage;
    Dr. John C. Lantis, MD, FACS, Chief and Professor of Surgery at Mount Sinai West Hospital and the Icahn School of Medicine, and key opinion leader on limb salvage and lower extremity wound healing;
    Dr. Brock A. Liden, DPM, FABWH, FAPWCA, board-certified in Podiatry, attending physician at WAFL, and expert lecturer on wound care, podiatric medicine, surgery, and practice management; and,
    Dr. Terry A. Treadwell, MD, FACS is a vascular surgeon, Medical Director of the Institute of Advanced Wound Care in Montgomery, Alabama, and renowned lecturer on chronic wound care.

The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System

Retrieved on: 
Monday, December 5, 2022
Centers for Medicare & Medicaid Services, Wound healing, Level 2, Hemostasis, Food and Drug Administration Amendments Act of 2007, Mouth ulcer, Food, FDA, News, Biotechnology, Healthcare Common Procedure Coding System, Center for Medicare and Medicaid Innovation, Risk, Drug Quality and Security Act, Medicare, Patient, HCPCS, OTCQB, AC5, Trauma, Therapy, Skin, Arch, Pharmaceutical industry

The preliminary recommendation was discussed at CMS’ First Biannual 2022 HCPCS Public Meeting, which was held on November 30, 2022.

Key Points: 
  • The preliminary recommendation was discussed at CMS’ First Biannual 2022 HCPCS Public Meeting, which was held on November 30, 2022.
  • The HCPCS code would better enable providers to bill third party payors for AC5 that is used in doctors’ offices.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.
  • Arch has received regulatory clearance to market AC5® Advanced Wound System in the United States and AC5® Topical Hemostat in Europe.